{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:50:46Z","timestamp":1785901846197,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.intimp.2025.115643","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:49:38Z","timestamp":1760543378000},"page":"115643","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2\/STAT3 signaling pathway"],"prefix":"10.1016","volume":"167","author":[{"given":"Xinyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingru","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangying","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10225","key":"10.1016\/j.intimp.2025.115643_bb0005","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017 [J]","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.intimp.2025.115643_bb0010","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfz174","article-title":"A single number for advocacy and communication\u2014worldwide more than 850 million individuals have kidney diseases [J]","volume":"34","author":"Jager","year":"2019","journal-title":"Nephrol. Dial. Transplant."},{"issue":"13","key":"10.1016\/j.intimp.2025.115643_bb0015","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J]","volume":"351","author":"Go As","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.intimp.2025.115643_bb0020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease [J]","volume":"74","author":"Sarnak","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.intimp.2025.115643_bb0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.yjmcc.2016.06.001","article-title":"Physiological and pathological cardiac hypertrophy","volume":"97","author":"Shimizu","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"9731","key":"10.1016\/j.intimp.2025.115643_bb0030","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis [J]","volume":"375","author":"Consortium","year":"2010","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.intimp.2025.115643_bb0035","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.7150\/ijbs.83432","article-title":"A novel mouse model of heart failure with preserved ejection fraction after chronic kidney disease induced by retinol through JAK\/STAT pathway [J]","volume":"19","author":"Liu","year":"2023","journal-title":"Int. J. Biol. Sci."},{"issue":"2","key":"10.1016\/j.intimp.2025.115643_bb0040","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/ehf2.14947","article-title":"Systemic aging fuels heart failure: molecular mechanisms and therapeutic avenues [J]","volume":"12","author":"Fang","year":"2024","journal-title":"ESC Heart Failure"},{"issue":"4","key":"10.1016\/j.intimp.2025.115643_bb0045","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1159\/000435838","article-title":"Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment [J]","volume":"5","author":"Di Lullo","year":"2015","journal-title":"Cardiorenal Medicine"},{"issue":"5","key":"10.1016\/j.intimp.2025.115643_bb0050","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s10741-023-10318-1","article-title":"Implications of uremic cardiomyopathy for the practicing clinician: an educational review [J]","volume":"28","author":"Hiraiwa","year":"2023","journal-title":"Heart Fail. Rev."},{"issue":"11","key":"10.1016\/j.intimp.2025.115643_bb0055","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/ndt\/gfu223","article-title":"Left ventricular function and chronic kidney disease: how soon does it start?","volume":"29","author":"Campese","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"6","key":"10.1016\/j.intimp.2025.115643_bb0060","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a European renal best practice position statement [J]","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"issue":"21","key":"10.1016\/j.intimp.2025.115643_bb0065","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"Treat investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease [J]","volume":"361","author":"Pfeffer Ma","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115643_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease [J]","volume":"153","author":"Palmer Sc","year":"2010","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2025.115643_bb0075","first-page":"65","article-title":"Pegmolesatide for the treatment of anemia in patients undergoing dialysis: a randomized clinical trial","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"3","key":"10.1016\/j.intimp.2025.115643_bb0080","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ekir.2024.12.002","article-title":"Randomized trial of Pegmolesatide for the treatment of Anemia in patients with nondialysis CKD [J]","volume":"10","author":"Xie","year":"2025","journal-title":"Kidney International Reports"},{"issue":"1","key":"10.1016\/j.intimp.2025.115643_bb0085","article-title":"Overview of preclinical and phase II clinical studies on Pegmolesatide\u2019s long-term erythropoiesis stimulating effect via EPOR-mediated signal transduction [J]","volume":"23","author":"Ma","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2025.115643_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2018.04.001","article-title":"Computational design and experimental characterization of a novel \u03b2-common receptor inhibitory peptide [J]","volume":"104","author":"Kilar","year":"2018","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.intimp.2025.115643_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100947","article-title":"EPO-mimetic peptide Pegmolesatide therapy for pure red cell aplasia in a patient with non-dialysis-dependent type 1 diabetic nephropathy: A case report [J]","volume":"7","author":"Chen","year":"2025","journal-title":"Kidney Med."},{"issue":"8","key":"10.1016\/j.intimp.2025.115643_bb0100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/s41581-022-00576-x","article-title":"Cardiac metabolic remodelling in chronic kidney disease","volume":"18","author":"Patel","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.intimp.2025.115643_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113751","article-title":"Induction of JAK2\/STAT3 pathway contributes to protective effects of different therapeutics against myocardial ischemia\/reperfusion [J]","volume":"155","author":"Mahdiani","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115643_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108780","article-title":"Captopril attenuates TAC-induced heart failure via inhibiting Wnt3a\/\u03b2-catenin and Jak2\/Stat3 pathways [J]","volume":"113","author":"Zhang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.115643_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.755077","article-title":"Magnolol attenuates right ventricular hypertrophy and fibrosis in hypoxia-induced pulmonary arterial hypertensive rats through inhibition of the JAK2\/STAT3 signaling pathway [J]","volume":"12","author":"Fu","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115643_bb0120","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1177\/2047487312462827","article-title":"Exercise rescued chronic kidney disease by attenuating cardiac hypertrophy through the cardiotrophin-1\u2192LIFR\/gp 130\u2192JAK\/STAT3 pathway [J]. European journal of","volume":"21","author":"Chen","year":"2012","journal-title":"Prev. Cardiol."},{"issue":"9","key":"10.1016\/j.intimp.2025.115643_bb0125","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/jcmm.17267","article-title":"Periplocymarin alleviates pathological cardiac hypertrophy via inhibiting the JAK2\/STAT3 signalling pathway [J]","volume":"26","author":"Fan","year":"2022","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.intimp.2025.115643_bb0130","doi-asserted-by":"crossref","first-page":"12772","DOI":"10.1080\/21655979.2022.2073145","article-title":"Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2\/signal transducer and activator of transcription 3 (JAK-2\/STAT3) signaling pathway [J]","volume":"13","author":"Chen","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.intimp.2025.115643_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.intimp.2019.01.013","article-title":"IL-37 attenuates allergic process via STAT6\/STAT3 pathways in murine allergic rhinitis [J]","volume":"69","author":"Wang","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.115643_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113134","article-title":"Interleukin(IL)-37 attenuates isoproterenol (ISO)-induced cardiac hypertrophy by suppressing JAK2\/STAT3-signaling associated inflammation and oxidative stress [J]","volume":"142","author":"Guo","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2025.115643_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6027421","article-title":"Electroacupuncture at GV20 and ST36 exerts neuroprotective effects via the EPO-mediated JAK2\/STAT3 pathway in cerebral ischemic rats [J]","volume":"2017","author":"Xu","year":"2017","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115643_bb0150","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jvs.2013.06.054","article-title":"Potential role of erythropoietin receptors and ligands in attenuating apoptosis and inflammation in critical limb ischemia [J]","volume":"60","author":"Joshi","year":"2014","journal-title":"J. Vasc. Surg."},{"issue":"9","key":"10.1016\/j.intimp.2025.115643_bb0155","doi-asserted-by":"crossref","first-page":"3513","DOI":"10.1073\/pnas.1214099110","article-title":"Alternative erythropoietin-mediated signaling prevents secondary microvascular thrombosis and inflammation within cutaneous burns [J]","volume":"110","author":"Bohr","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"19\u201320","key":"10.1016\/j.intimp.2025.115643_bb0160","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.lfs.2012.04.012","article-title":"Erythropoietin alleviates post-ischemic injury of rat hearts by attenuating nitrosative stress [J]","volume":"90","author":"Lu","year":"2012","journal-title":"Life Sci."},{"key":"10.1016\/j.intimp.2025.115643_bb0165","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ejphar.2016.05.024","article-title":"Role of JAK-STAT pathway in reducing cardiomyocytes hypoxia\/reoxygenation injury induced by S1P postconditioning [J]","volume":"784","author":"Wang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115643_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The role of JAK\/STAT signaling pathway and its inhibitors in diseases [J]","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115643_bb0175","first-page":"1027","article-title":"Differential effects of erythropoietin administration and overexpression on venous thrombosis in mice [J]","volume":"124","author":"Stockhausen","year":"2023","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.intimp.2025.115643_bb0180","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of Anemia in chronic kidney disease: beyond erythropoietin [J]","volume":"38","author":"Hanna","year":"2020","journal-title":"Adv. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925016340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T12:32:30Z","timestamp":1765456350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925016340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":36,"alternative-id":["S1567576925016340"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115643","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegmolesatide ameliorates indoxyl sulfate-induced cardiomyocyte hypertrophy through modulating the EPOR-CD131-dependent JAK2\/STAT3 signaling pathway","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115643","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115643"}}